How Hims & Hers Reached a $4.3BN Market Cap on $2.3BN of Revenue | Andrew Dudum
Hims & Hers CEO Andrew Dudum explains how the company cut GLP-1 prices 80% in 18 months and why free at-home blood testing is the next frontier.
- Hims acquired Eucalyptus, its largest international competitor, for ~$1.5B, making it the dominant digital health player in Australia, UK, and Germany.
- GLP-1 drug prices dropped from ~$2,000 to $149 in 18 months; Dudum attributes this partly to consumer and regulatory pressure Hims helped generate.
- Hims acquired YBio Health, an at-home blood collection device (~$2 manufacturing cost), with a goal to offer 50-biomarker panels free as part of membership.
- Hims treats 10,000–20,000 patients per day, which Dudum claims makes it the largest healthcare system in the US by patient volume.
- Weight loss is not the majority of revenue; Hims runs ~10 independent clinical categories as a venture portfolio, including peptides as the next likely headline category.
- AI has had the biggest measurable impact in customer support, clinical provider quality, and marketing design output — same team producing 3–4x the creative volume.
- Dudum’s biggest self-identified mistake: being 1–2 years too slow forcing the company to rebuild patient interaction workflows around AI.
- Hims plans to remain ~2,000–3,000 employees through 2030 despite scale, constrained mainly by physical pharmacy fulfillment labor requirements.
2026-04-04 · Watch on YouTube
